The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: A phase III randomized trial of the Gynecologic Oncology Group.
Krishnansu Sujata Tewari
No relevant relationships to disclose
Michael Sill
No relevant relationships to disclose
Harry J. Long
No relevant relationships to disclose
Lois M. Ramondetta
No relevant relationships to disclose
Lisa Michelle Landrum
No relevant relationships to disclose
Ana Oaknin
No relevant relationships to disclose
Thomas J Reid
No relevant relationships to disclose
Mario M. Leitao
No relevant relationships to disclose
Helen E Michael
No relevant relationships to disclose
Bradley J. Monk
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech